MIPS ADVANCES TO THE MID CAP SEGMENT AFTER NASDAQ STOCKHOLM’S YEARLY REVIEW OF LISTED COMPANIES’ MARKET VALUE. THE MOVE WILL BE EFFECTED AS OF 2 JANUARY 2019. December 18, 2018 Nasdaq Stockholm’s yearly review is based on the average market value in November. This year’s review resulted ... read more

GAITHERSBURG, Md., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced updates to its clinical programs and plans to further expand its pipeline. NasoVAX As previously announced in September 2018, a monovalent version o... read more

Stockholm – December 13, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) will hold its Capital Markets Day in New York tomorrow, Dec 14, between 14:30 – 17:00 CET (8:30-11:00 ET). For those who cannot attend in New York, you can follow this via a webcast. The registration for th... read more

Uppsala, Sweden – December 13, 2018 - Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the Company will regain the rights to Zubsolv (buprenorphine and naloxone sublingual tablet) for the treatment of opioid dep... read more

Oslo, Norway, 12 December 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that CEO Øystein Soug presented today at DNB 9th Annual Nordic Healthcare Conference in Oslo, Norway. The presentation pr... read more